A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

Mild to Moderate COVID-19 Clinical Trial

Official title:
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants With Mild to Moderate COVID-19

Status Recruiting

Clinical Trial Summary

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05941793
Study type	Interventional
Source	Oneness Biotech Co., Ltd.
Contact	Reo Yang
Phone	02-2703-1098
Email	Reo.Yang@onenessbio.com.tw
Status	Recruiting
Phase	Phase 2
Start date	September 11, 2023
Completion date	November 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04705844` - Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)	Phase 3
Terminated	`NCT04521296` - Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo	Phase 2/Phase 3
Completed	`NCT05582629` - JT001 (VV116) for the Treatment of COVID-19	Phase 3
Completed	`NCT05620160` - Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19	Phase 3
Recruiting	`NCT06197217` - Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19	Phase 3
Recruiting	`NCT05675072` - Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19	Phase 2/Phase 3
Terminated	`NCT05242042` - JT001 (VV116) for the Early Treatment of COVID-19	Phase 2/Phase 3
Suspended	`NCT04711863` - Fluvoxamine for Adults With Mild to Moderate COVID-19	Phase 2